Evaluation of a New Commercially Available Immunoglobulin M Capture Enzyme-Linked Immunosorbent Assay for Diagnosis of Dengue Virus Infection
Madhuri Namekara b, Esther M. Ellisa b, Maile O'Connella b, Joe Elmc, Alexandra Gurarya b, Sarah Y. Parkc, Allison A. Imriea b d, Vivek R. Nerurkara b
- aDepartment of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA
- bPacific Center for Emerging Infectious Diseases Research, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA
- cState of Hawaii Department of Health, Honolulu, Hawaii, USA
- dUniversity of Western Australia, Perth, Western Australia, Australia
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
We evaluated the FDA-cleared InBios dengue virus (DENV) IgM capture enzyme-linked immunosorbent assay (ELISA) for qualitative detection of anti-DENV IgM antibodies from 79 serum samples obtained from dengue virus-infected patients or suspected dengue cases. The agreement, sensitivity, and specificity of the InBios assay compared to the gold standard in-house DENV IgM capture ELISA were 94, 92, and 94%, respectively. We conclude that the InBios DENV IgM capture ELISA can be effectively used for rapid diagnosis of acute or recent DENV infection.
TL;DRIt is concluded that the FDA-cleared InBios DENV IgM capture ELISA can be effectively used for rapid diagnosis of acute or recent DENV infection. (Semantic Scholar)